Loading...
01/11 04:42
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: improved revenue and EPS guidance, stable demand environment, and cost-saving measures are positive. However, uncertainties in divestitures, DSA growth, and reliance on nascent NAMs technologies add caution. The Q&A section highlighted analyst concerns about divestitures and growth forecasts. Despite raised guidance, the lack of clear growth predictions and divestiture specifics tempers optimism, leading to a neutral sentiment.
Revenue $1 billion in the third quarter of 2025, a 0.5% decrease year-over-year. On an organic basis, revenue declined 1.6% due to declines in both the DSA and Manufacturing segments, partially offset by an increase in the RMS segment. The decline was attributed to tighter budgets from small and midsized biotech clients and the loss of a large commercial client in the CDMO business.
Operating Margin 19.7% in the quarter, a decrease of 20 basis points year-over-year. The decline was driven by lower sales volume in the DSA segment and lower commercial CDMO revenue in the Manufacturing segment.
Earnings Per Share (EPS) $2.43 in the third quarter, a 6.2% decline from the third quarter of last year. The decline was primarily due to a significant year-over-year tax rate increase, totaling $0.24 per share, due to new tax legislation.
DSA Segment Revenue $600.7 million in the third quarter, a 3.1% year-over-year decrease on an organic basis. The decline was driven by lower revenue for both Discovery and Safety Assessment Services, partially offset by a modest benefit from favorable study mix.
RMS Segment Revenue $213.5 million, an increase of 6.5% on an organic basis compared to the third quarter of 2024. The growth was driven by the favorable timing of NHP shipments.
Manufacturing Segment Revenue $190.7 million, a 5.1% decrease on an organic basis from the third quarter of last year. The decline was largely driven by lower commercial revenue from CDMO clients.
Free Cash Flow $178.2 million in the third quarter, compared to $213.1 million in the same period last year, representing a decrease primarily driven by lower earnings.
CapEx $35.6 million or approximately 3.5% of revenue in the third quarter, compared to $38.7 million last year, reflecting a focus on disciplined capital spending.
NAMs (New Approach Methodologies): Focus on advancing NAMs capabilities, including next-generation sequencing solutions, recombinant bacterial endotoxin tests, and in vitro immunogenicity assessments. These efforts aim to reduce reliance on animal models and enhance drug development efficiency.
Geographic Presence: Evaluating opportunities to enhance geographic presence as part of growth initiatives.
Cost Savings Initiatives: Implemented restructuring initiatives expected to save $225 million annually by 2026, representing a 5% cost reduction. Additional process improvements and procurement synergies to save $70 million annually by 2026.
Operational Efficiency: Adopting a global business services model and enhancing client relationships through technology platforms and clinical data access.
Portfolio Refinement: Plan to divest underperforming or non-core businesses, representing 7% of 2025 revenue, to focus on profitable growth opportunities. Expected to result in $0.30 per share earnings accretion annually post-divestiture.
Capital Allocation: Board approved a $1 billion stock repurchase authorization, replacing the previous authorization. Focus on balancing acquisitions, stock repurchases, and debt repayment.
Market Conditions: Uncertainty in end markets and cautious client demand, particularly from small and midsized biotech clients, due to tighter budgets and a softer biotech funding environment.
Competitive Pressures: Loss of a large commercial client in the CDMO business, impacting revenue and creating a $20 million revenue headwind in the second half of the year.
Regulatory Hurdles: Biologics Testing business facing lower sample volumes due to project delays or regulatory challenges for several large clients.
Supply Chain Disruptions: Higher third-party NHP sourcing costs due to procurement of additional models to support better-than-expected demand.
Economic Uncertainties: Impact of new tax legislation (OB3 Act) and global minimum tax provisions, increasing the non-GAAP tax rate by 700 basis points year-over-year.
Strategic Execution Risks: Challenges in divesting underperforming or non-core businesses, which represent 7% of estimated 2025 revenue, and ensuring timely completion by mid-2026.
Operational Efficiency: Pressure on operating margins in DSA and Manufacturing segments due to lower sales volume and higher staffing costs.
Revenue Guidance: For 2025, organic revenue is expected to decline by 1.5% to 2.5%, with reported revenue declining by 0.5% to 1.5%. Fourth-quarter revenue is projected to range from flat to a low single-digit decline year-over-year.
Earnings Per Share (EPS) Guidance: Non-GAAP EPS for 2025 is expected to be in the range of $10.10 to $10.30, reflecting a $0.10 increase from the midpoint of the prior guidance range. Fourth-quarter EPS is expected to be flat to 10% below the third-quarter level of $2.43.
Operating Margin Outlook: The full-year operating margin is expected to be flat to a 30 basis point decline. Fourth-quarter margins will face pressure in the DSA segment due to higher staffing and NHP sourcing costs, and in the RMS segment due to timing of NHP shipments and seasonal trends.
Capital Expenditures and Free Cash Flow: CapEx for 2025 is projected to be approximately $200 million, representing about 5% of revenue. Free cash flow is expected to range from $470 million to $500 million, an increase from the prior outlook of $430 million to $470 million.
DSA Segment Outlook: DSA revenue for 2025 is expected to decline by 2.5% to 3.5% on an organic basis. Fourth-quarter DSA revenue is projected to be stable to modestly below the third-quarter level.
RMS Segment Outlook: RMS revenue for 2025 is expected to be flat to slightly positive on an organic basis. Fourth-quarter RMS revenue will be lower due to the acceleration of NHP shipments into the third quarter and normal seasonal trends.
Manufacturing Segment Outlook: Manufacturing revenue for 2025 is expected to be flat to slightly lower on an organic basis. Fourth-quarter revenue is expected to improve due to year-end ordering patterns in the Microbial Solutions business.
Biotech and Biopharma Demand Trends: Biotech funding and proposal activity improved in the third quarter, with cautious optimism for continued improvement in demand over the coming quarters. Biopharma demand is expected to rebound, supported by improved funding and proposal activity.
Strategic Divestitures: The company plans to divest underperforming or non-core businesses, representing approximately 7% of estimated 2025 revenue. These divestitures are expected to be completed by mid-2026 and result in non-GAAP earnings accretion of at least $0.30 per share annually.
Cost Savings Initiatives: Restructuring initiatives are expected to result in $225 million in cumulative annualized cost savings by 2026, with an additional $70 million in annual savings from process improvements and operating efficiencies.
Stock Repurchase Authorization: The Board of Directors approved a new $1 billion stock repurchase authorization, replacing the previous authorization. Since August 2024, $450.7 million in common stock had been repurchased under the previous authorization. The company will evaluate the level of stock repurchases considering valuation, growth prospects, expected returns, earnings accretion, leverage, and other cash uses.
The earnings call reveals mixed signals: improved revenue and EPS guidance, stable demand environment, and cost-saving measures are positive. However, uncertainties in divestitures, DSA growth, and reliance on nascent NAMs technologies add caution. The Q&A section highlighted analyst concerns about divestitures and growth forecasts. Despite raised guidance, the lack of clear growth predictions and divestiture specifics tempers optimism, leading to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
